Latest News

A 10-protein serum signature identified through longitudinal proteomics significantly stratified relapse risk in NMOSD patients, with the 2 strongest markers showing an association with relapse more than 8 months out on average.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is retinal biomarkers for central nervous system disease!

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 3, 2026.

The 510(k) clearance was supported by a 3-study, 159-patient registrational program showing a 45.5% increase in response rate vs physical therapy alone, and includes Medicare coverage at launch.

New phase 2b PARADIGM data showed PrimeC significantly reduced neuron-derived TDP-43 levels in patients with ALS while reinforcing previously reported improvements in disease progression and survival.

Tom Fuchs, MD, PhD, postdoctoral researcher at the MS Center at Amsterdam University Medical Center, shared his reaction to the European Commission's approval of tolebrutinib for nonrelapsing secondary progressive MS.

Results from the Baby-COMET study of avalglucosidase alfa in infantile-onset Pompe disease will support a planned US regulatory submission for a label extension, anticipated in the second half of 2026.

Twelve-month phase 1/2 data show SKY-0515-treated patients trending favorably versus natural history expectations across motor, functional, and cognitive endpoints, while 65% of patients and 50% of clinicians reported disease improvement.

The professor of neurology at Wake Forest School of Medicine discussed the evolution of sleep medicine education, its relevance across neurologic specialties, and advice for early-career clinicians.

The FDA accepted supplemental applications seek to convert the accelerated approvals of casimersen and golodirsen to traditional approvals in patients with Duchenne muscular dystrophy.

Additional analyses from a phase 2 study evaluating the effects of zervimesine on hallucination in DLB will be presented at the Alzheimer's Association International Conference 2026 .

In the exploratory phase 2 RoAD study, PrimeC demonstrated biomarker changes consistent with target engagement across multiple neurodegenerative pathways, informing the design of future Alzheimer's disease trials.